Epidemiological burden, risk factors, and recent therapeutic advances in chronic obstructive pulmonary disease
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease that is certainly preventable and treatable and is caused due to the continuous exposure to noxious substances and toxic gases and is characterized by airflow limitation and chronic inflammation in the lungs coupled with persisten...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bangladesh Society for Microbiology, Immunology, and Advanced Biotechnology
2023-04-01
|
| Series: | Journal of Advanced Biotechnology and Experimental Therapeutics |
| Subjects: | |
| Online Access: | http://www.ejmanager.com/fulltextpdf.php?mno=103731 |
| _version_ | 1797973843652902912 |
|---|---|
| author | Ayilya Bakthavatchalam Loganathan Nazeer Rasool Abdul |
| author_facet | Ayilya Bakthavatchalam Loganathan Nazeer Rasool Abdul |
| author_sort | Ayilya Bakthavatchalam Loganathan |
| collection | DOAJ |
| description | Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease that is certainly preventable and treatable and is caused due to the continuous exposure to noxious substances and toxic gases and is characterized by airflow limitation and chronic inflammation in the lungs coupled with persistent symptoms in the respiratory tract leading to obstructive bronchiolitis and parenchymal emphysema. The incidence and progression of COPD is a complicated pathological phenomenon and the overall severity is due to its exacerbations and comorbidities in individuals. Further, COPD is a major contributor to the global years of life lost and by 2030 it would be the third leading causes of mortality in the world. Also, knowledge on COPD, its associated conditions and the clinical understanding of the disease date back to the 16th century. The prevalence, morbidity and mortality may vary across the globe based on their exposure to smoking, tobacco, occupational pollutants, indoor pollution, outdoor air pollution, gender, age and genetic inheritance. Considering the continuous exposure to toxic substances and aging of the general population, the burden and prevalence of COPD are estimated to increase substantially in the coming years. Furthermore, COVID-19 patients with pre-existing COPD conditions suffer from severe disease progression and delay in recovery. [ J Adv Biotechnol Exp Ther 2023; 6(1.000): 109-122] |
| first_indexed | 2024-04-11T04:10:42Z |
| format | Article |
| id | doaj.art-576a5e173d854bdaa38ff4c2b9610db3 |
| institution | Directory Open Access Journal |
| issn | 2616-4760 |
| language | English |
| last_indexed | 2024-04-11T04:10:42Z |
| publishDate | 2023-04-01 |
| publisher | Bangladesh Society for Microbiology, Immunology, and Advanced Biotechnology |
| record_format | Article |
| series | Journal of Advanced Biotechnology and Experimental Therapeutics |
| spelling | doaj.art-576a5e173d854bdaa38ff4c2b9610db32023-01-01T08:49:41ZengBangladesh Society for Microbiology, Immunology, and Advanced BiotechnologyJournal of Advanced Biotechnology and Experimental Therapeutics2616-47602023-04-016110912210.5455/jabet.2023.d110103731Epidemiological burden, risk factors, and recent therapeutic advances in chronic obstructive pulmonary diseaseAyilya Bakthavatchalam Loganathan0Nazeer Rasool Abdul1Biopharmaceuticals lab, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamilnadu, India Biopharmaceuticals lab, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamilnadu, IndiaChronic Obstructive Pulmonary Disease (COPD) is a progressive disease that is certainly preventable and treatable and is caused due to the continuous exposure to noxious substances and toxic gases and is characterized by airflow limitation and chronic inflammation in the lungs coupled with persistent symptoms in the respiratory tract leading to obstructive bronchiolitis and parenchymal emphysema. The incidence and progression of COPD is a complicated pathological phenomenon and the overall severity is due to its exacerbations and comorbidities in individuals. Further, COPD is a major contributor to the global years of life lost and by 2030 it would be the third leading causes of mortality in the world. Also, knowledge on COPD, its associated conditions and the clinical understanding of the disease date back to the 16th century. The prevalence, morbidity and mortality may vary across the globe based on their exposure to smoking, tobacco, occupational pollutants, indoor pollution, outdoor air pollution, gender, age and genetic inheritance. Considering the continuous exposure to toxic substances and aging of the general population, the burden and prevalence of COPD are estimated to increase substantially in the coming years. Furthermore, COVID-19 patients with pre-existing COPD conditions suffer from severe disease progression and delay in recovery. [ J Adv Biotechnol Exp Ther 2023; 6(1.000): 109-122]http://www.ejmanager.com/fulltextpdf.php?mno=103731copdmorbiditymortalityprevalencesmokingepidemiology |
| spellingShingle | Ayilya Bakthavatchalam Loganathan Nazeer Rasool Abdul Epidemiological burden, risk factors, and recent therapeutic advances in chronic obstructive pulmonary disease Journal of Advanced Biotechnology and Experimental Therapeutics copd morbidity mortality prevalence smoking epidemiology |
| title | Epidemiological burden, risk factors, and recent therapeutic advances in chronic obstructive pulmonary disease |
| title_full | Epidemiological burden, risk factors, and recent therapeutic advances in chronic obstructive pulmonary disease |
| title_fullStr | Epidemiological burden, risk factors, and recent therapeutic advances in chronic obstructive pulmonary disease |
| title_full_unstemmed | Epidemiological burden, risk factors, and recent therapeutic advances in chronic obstructive pulmonary disease |
| title_short | Epidemiological burden, risk factors, and recent therapeutic advances in chronic obstructive pulmonary disease |
| title_sort | epidemiological burden risk factors and recent therapeutic advances in chronic obstructive pulmonary disease |
| topic | copd morbidity mortality prevalence smoking epidemiology |
| url | http://www.ejmanager.com/fulltextpdf.php?mno=103731 |
| work_keys_str_mv | AT ayilyabakthavatchalamloganathan epidemiologicalburdenriskfactorsandrecenttherapeuticadvancesinchronicobstructivepulmonarydisease AT nazeerrasoolabdul epidemiologicalburdenriskfactorsandrecenttherapeuticadvancesinchronicobstructivepulmonarydisease |